Literature DB >> 31092995

MicroRNA-183-5p: A New Potential Marker for Prostate Cancer.

Mohammad Waseem1,2, Mohammad Kaleem Ahmad1, Mohammad Serajuddin2, Ved Bhaskar3, Satya Narain Sankhwar3, Abbas Ali Mahdi1.   

Abstract

The microRNA (miR)-183-5p is expressed at high level in the majority of cancer. The purpose of present study was to investigate the role of oncogenic miR-183-5p in prostate cancer (PCa) as biomarker. We carried out our experiment in 50 prostate cancer patients and 40 patients of benign prostatic hyperplasia (BPH) and 40 adjacent controls tissue. The expression of miR-183-5p was evaluated through reverse transcription qualitative polymerase chain reaction. We found that the expression of miR-183-5p in PCa tissue was significantly up regulated as compared to BPH patients and adjacent normal tissues as control. Additionally, miR-183 expression was correlated with higher prostate-specific antigen, higher Gleason Score and metastatic condition. A receiver operating characteristic curve analysis revealed that miR-183-5p distinguished PCa patients from BPH patients and also from control. In conclusion, our data suggest that oncogenic miR-183-5p may be useful as a new tissue specific diagnostic biomarker in prostate cancer.

Entities:  

Keywords:  BPH; MicroRNA; Prostate cancer; RT-PCR and diagnosis

Year:  2017        PMID: 31092995      PMCID: PMC6486929          DOI: 10.1007/s12291-017-0731-9

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  36 in total

Review 1.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

2.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

3.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

4.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

5.  Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.

Authors:  Hideaki Ijichi; Motoyuki Otsuka; Keisuke Tateishi; Tsuneo Ikenoue; Takayuki Kawakami; Fumihiko Kanai; Yoshihiro Arakawa; Naohiko Seki; Kiyoshi Shimizu; Kohei Miyazono; Takao Kawabe; Masao Omata
Journal:  Oncogene       Date:  2004-02-05       Impact factor: 9.867

6.  MicroRNA expression profiling in prostate cancer.

Authors:  Kati P Porkka; Minja J Pfeiffer; Kati K Waltering; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

7.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.

Authors:  Annika Schaefer; Monika Jung; Hans-Joachim Mollenkopf; Ina Wagner; Carsten Stephan; Florian Jentzmik; Kurt Miller; Michael Lein; Glen Kristiansen; Klaus Jung
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

8.  Switching from repression to activation: microRNAs can up-regulate translation.

Authors:  Shobha Vasudevan; Yingchun Tong; Joan A Steitz
Journal:  Science       Date:  2007-11-29       Impact factor: 47.728

9.  miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.

Authors:  E J Noonan; R F Place; D Pookot; S Basak; J M Whitson; H Hirata; C Giardina; R Dahiya
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

Review 10.  MicroRNA: implications for cancer.

Authors:  Stefanie Sassen; Eric A Miska; Carlos Caldas
Journal:  Virchows Arch       Date:  2007-11-27       Impact factor: 4.064

View more
  6 in total

1.  MiR-1273 g-3p Promotes Malignant Progression and has Prognostic Implications in Prostate Cancer.

Authors:  Yaxue Chang; Qian Deng; Zhenfeng Guan; Yongyi Cheng; Yi Sun
Journal:  Mol Biotechnol       Date:  2021-08-24       Impact factor: 2.695

2.  MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients.

Authors:  Lin Jin; Yue Luo; Ying-Chun Zhao; Hai Tao
Journal:  Cancer Manag Res       Date:  2021-01-27       Impact factor: 3.989

3.  miR-183-5p Aggravates Breast Cancer Development via Mediation of RGS2.

Authors:  Chihua Wu; Youlin Tuo; Gang Hu; Jing Luo
Journal:  Comput Math Methods Med       Date:  2021-11-20       Impact factor: 2.238

4.  Hsa-miR-183-5p Modulates Cell Adhesion by Repression of ITGB1 Expression in Prostate Cancer.

Authors:  Carolina Oliveira-Rizzo; María Carolina Ottati; Rafael Sebastián Fort; Santiago Chavez; Juan Manuel Trinidad; Andrés DiPaolo; Beatriz Garat; José Roberto Sotelo-Silveira; María Ana Duhagon
Journal:  Noncoding RNA       Date:  2022-01-18

Review 5.  Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?

Authors:  Folake Orafidiya; Lin Deng; Charlotte Lynne Bevan; Claire Emily Fletcher
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

6.  MicroRNA Dysregulation in Prostate Cancer.

Authors:  Vlad Horia Schitcu; Lajos Raduly; Andreea Nutu; Oana Zanoaga; Cristina Ciocan; Vlad Cristian Munteanu; Roxana Cojocneanu; Bogdan Petrut; Ioan Coman; Cornelia Braicu; Ioana Berindan-Neagoe
Journal:  Pharmgenomics Pers Med       Date:  2022-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.